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Abstract
A major unmet challenge in developing preventative treatment programs for osteoporosis is that the optimal
timing of treatment remains unknown. In this commentary we make the argument that the menopausal transition
(MT) is a critical period in a woman’s life for bone health, and that efforts aimed at reducing fracture risk later in life
may benefit greatly from strategies that treat women earlier with the intent of keeping bones strong as long as
possible. Bone strength is an important parameter to monitor during the MT because engineering principles can be
applied to differentiate those women that maintain bone strength from those women that lose bone strength and
are in need of early treatment. It is critical to understand the underlying mechanistic causes for reduced strength to
inform treatment strategies. Combining measures of strength with data on how bone structure changes during the
MT may help differentiate whether a woman is losing strength because of excessive bone resorption, insufficient
compensatory bone formation, trabeculae loss, or some combination of these factors. Each of these biomechanical
mechanisms may require a different treatment strategy to keep bones strong. The technologies that enable
physicians to differentially diagnose and treat women in a preventive manner, however, have lagged behind the
development of prophylactic treatments for osteoporosis. To take advantage of these treatment options, advances
in preventive treatment strategies for osteoporosis may require developing new technologies with imaging
resolutions that match the pace by which bone changes during the MT and supplementing a woman's bone
mineral density (BMD)-status with information from engineering-based analyses that reveal the structural and
material changes responsible for the decline in bone strength during the menopausal transition.
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The optimal management of osteoporosis remains unre-
solved [1]. Current diagnostic and treatment protocols
for osteoporosis are initiated when an individual’s areal
bone mineral density (aBMD) T-score falls below −2.5
[2]. Those with T-scores between −1 and −2.4 may also
be treated depending on whether they have additional
risk factors such as a prior fracture or a family history of
fractures. With this treatment strategy, one has to be-
come osteopenic or nearly osteoporotic to be diagnosed
and treated for osteoporosis. Having to suffer a fragility
fracture to be diagnosed and treated for osteoporosis is
like having to suffer a heart attack to be diagnosed and
treated for heart disease. Fortunately for cardiovascular
medicine, adoption of pre-clinical measures such as
blood pressure and serum lipoprotein profile and know-
ledge of major risk factors such as smoking status and
obesity allow primary care physicians to treat individuals
preventatively in advance of a catastrophic event. Regret-
tably for bone health, similar pre-clinical measures have
not yet been well developed for osteoporosis. The
current strategy generally identifies individuals with
osteoporosis after they have lost an appreciable amount
of bone and prophylactically treats them with the intent
of restoring the BMD that was lost during the previous
decade. This lagged diagnostic and treatment approach is
particularly problematic for women as they uniquely
experience the menopausal transition which is
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characterized by more rapid bone loss, thereby positioning
them at greater fracture risk during the postmenopause.
Further, this strategy is geared toward restoration rather
than prevention, and consequently places women at risk of
fracturing prior to treatment [2]. In this commentary, we
emphasize the need for better prevention methods that in-
clude detection of changes in bone strength during the
menopausal transition given knowledge of the significance
of this life stage for bone health as women transition to
old age. This strategy will give a voice to what has often
been characterized as a silent disease. However, know-
ledge gaps remain regarding the ideal window for treat-
ment and the type of information that would be clinically
useful for a successful prevention strategy.
Why is the menopausal transition important? To tran-
sition the current strategy for treating osteoporosis from
one that focuses on restoration toward one that focuses
on prevention will require the identification of new bio-
markers that monitor a woman’s bone health status earl-
ier in life and that identify those women who are in
need of early intervention. The menopausal transition is
associated with rapid changes in serum levels of follicle-
stimulating hormone (FSH), estradiol (E2), testosterone,
and inhibin A and B as well as a rapid bone strength
decline before the slower phase of postmenopausal bone
loss begins [1, 3–8]. Longitudinal studies have shown
that accelerated losses in BMD and bone strength
begin ~1–2 years prior to the final menstrual period
(FMP), continue at this rate until ~2–5 years after
the FMP, and then slow appreciably thereafter [1, 6].
Women may lose as much as 33 % of their bone
strength between 45 and 65 years of age before treat-
ments for osteoporosis typically begin [9]. The timing
and magnitude of bone mass and bone strength
changes have been well described on a population
average basis [1, 3–8, 10], but little is known about
the individual-level differences in bone mass and bone
strength during the menopausal transition.
Why do details of bone loss matter? Fracture prone
sites like the wrist, spine, and hip are comprised of a
relatively thin cortical shell that is supported by a highly
organized mass of trabecular bone (Fig. 1). These skel-
etal structures resemble a bridge, which is comprised of
a roadway (cortical bone) and its associated support
structure (trabecular bone). Following normal wear and
tear associated with daily usage, bits and pieces of the
bridge will naturally begin to fail. Imagine one morning
a sign is posted indicating there is a 5 % loss in the mass
of the bridge and to proceed with caution. Would you
drive over the bridge? You would likely want additional
information to know whether the 5 % loss in bridge-
mass included critical features like parts of the roadway
or a supporting beam needed to hold up the road. Fur-
ther, if you wanted to keep the bridge in good shape to
avoid a catastrophic event, you would want to know
which components were in need of repair and to set up
a regular maintenance schedule. We propose that the
same concepts for maintaining a bridge are needed to
maintain bone strength.
Which details of skeletal changes during the MT mat-
ter? To date, risk prediction has focused mainly upon
demographic characteristics, family history, medications,
lifestyle characteristics (e.g., smoking, alcohol intake),
fracture history, and aBMD [11]. aBMD has been used
successfully for screening postmenopausal women who
have osteoporosis, and identifying large changes in bone
mass that may increase a woman’s risk of fracturing [2].
However, BMD is not sufficiently sensitive to monitor
early declines in bone strength [9], which begin largely
during the menopausal transition [1, 3]. It has been hy-
pothesized that bone strength may be the more appro-
priate measure to predict fracture risk [9, 12, 13]. Bone
strength is a measure of the amount of load or force it
takes to cause a bone to fail, and thus is a critical param-
eter that differentiates whether a bone will break or not
during a simple fall [12, 14]. However, current treatment
paradigms often focus on maintaining BMD not
strength. This distinction is important because a woman
may lose bone mass without losing bone strength. This
phenomenon exists because bone has adaptive features
that allow it to compensate for bone loss to maintain
strength [15]. Bone forming cells (osteoblasts) can de-
posit small amounts of tissue on the outer surface of the
bone to mechanically offset the loss that occurs when
the bone resorbing cells (osteoclasts) remove tissue on
the inner surface [16–19]. Thus, bones tend to become
wider with aging, a phenomenon that is thought to help
maintain bone strength [16, 20, 21]. Because of the way
bones are loaded during daily activities, only a small
amount of new tissue needs to be deposited on the outer
surface to offset a large amount of loss near the inner
surface [21, 22]. Consequently, some women may show
a net loss of bone mass while maintaining bone strength.
Whether fracture risk depends on the degree to which
the newly deposited tissue on the outer surface mechan-
ically offsets the bone loss on the inner surface is not
fully understood [20, 23]. Critically, the amount of new
tissue deposited on the outer bone surface declines dur-
ing the menopausal transition and is only a fraction of
premenopausal levels by age 65 [23]. Thus, the window
for most efficacious treatment for maintaining bone
strength may be during the menopausal transition.
Knowing a woman’s bone strength is important, but is
not sufficient by itself to inform clinicians on how best
to treat women in a personalized preventative manner.
The details of how bone changes with aging, in particu-
lar the balance between bone resorption and bone for-
mation at all structural levels, are needed to inform
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clinicians how to keep bones strong during the meno-
pausal transition and the postmenopausal years [21, 23].
Translational studies are needed to define the different
ways in which women lose bone strength. Combining
measures of strength with data on how bone structure
changes during the MT may help differentiate whether a
woman is losing strength because of excessive resorp-
tion, insufficient formation, or some combination of
these factors. These outcomes may require different
treatment strategies to maintain strength [24]. For ex-
ample, women exhibiting excessive bone resorption may
be better treated with an anti-resorptive therapy,
whereas a woman with narrow bones and low periosteal
expansion may be better treated with an anabolic ther-
apy [25].
The armamentarium of prophylactic treatments for
osteoporosis has matured faster than the clinical adop-
tion of technologies that enable physicians to differen-
tially diagnose and treat individuals in a preventive
manner. Serum biomarkers of bone resorption and for-
mation are informative of system-wide changes in bone
structure, but these biomarkers do not inform on the
magnitude and location of bone loss and gain at individ-
ual anatomical sites (e.g., femur, distal radius, spine)
[26], which is needed to understand how bone strength
changed. Periosteal expansion, endocortical resorption,
trabecular loss, and increased porosity can all be mea-
sured using existing technologies [23, 27–31]. Hand
radiographs offer an inexpensive alternative from which
bone structural changes can be assessed over time
[32–36], possibly beginning at a premenopausal age
[22]. The potential costs and apparent impracticality
of acquiring structural assessments at multiple time points
are recognized deterrents to general adoption of a preven-
tion strategy. However, additional translational research
that focuses on understanding how precipitating biological
events occurring during the menopausal transition define
fracture risk later during the aging process would break
the silence of this disease, and potentially identify new
technologies, biomarkers, or baseline characteristics that
accurately predict individual trajectories of bone loss and
gain over time and that can be incorporated into the clinic
inexpensively and conveniently.
Conclusions
Accumulating evidence indicates that there are substan-
tive changes in bone strength during the menopausal
transition. Many challenges remain to give a voice to a
silent disease by better understanding how events during
the menopausal transition affect fracture risk during the
postmenopausal years. These include identifying bio-
markers that reveal the details of bone loss and gain;
identifying individual or combinations of biomarkers
that can be used to identify women in need of early
intervention; testing whether peripheral skeletal sites
(e.g., metacarpals, tibia, wrist) can be used as proxies of
strength declines at fracture-prone sites like the prox-
imal femur and spine; understanding how changes in
Fig. 1 Sagittal sections derived from 3-dimensional nanoComputed Tomography images (nanotom-s; phoenix|x-ray, GE Sensing & Inspection
Technologies, GmbH; Wunstorf, Germany) of cadaveric proximal femurs for two women, one 24 years old and the other 54 years old, convey
how bone loss occurs non-uniformly with aging and predominantly in the region used to measure aBMD with DEXA. Maintaining bone strength
is analogous to maintaining a bridge, where all critical structural components must be recognized and targeted to keep the structure intact and
functioning to prevent a catastrophic failure event
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hormones affect the balance between bone resorption
and formation at all structural levels and how this
balance affects strength; and conducting translational
studies that identify the mechanisms responsible for
inter-individual differences in skeletal aging, particu-
larly during the menopausal transition. Taking advan-
tage of the data within existing longitudinal studies of
women transitioning through the menopause, includ-
ing the Michigan Bone Health and Metabolism Study
[37], the Study of Women’s Health Across the Nation
[8, 38], and the Melbourne Women’s Midlife Health
Project [39], will be extremely helpful in resolving
these knowledge gaps and moving from a restoration
to a prevention treatment strategy.
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